[1]
|
Rosenfield, R.L. and Ehrmann, D.A. (2016) The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 37, 467-520.
https://doi.org/10.1210/er.2015-1104
|
[2]
|
Franks, S. (2008) Polycystic Ovary Syndrome in Adolescents. International Journal of Obesity, 32, 1035.
https://doi.org/10.1038/ijo.2008.61
|
[3]
|
Burghen, G.A., Givens, J.R. and Kitabchi, A.E. (1980) Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease. The Journal of Clinical Endocrinology & Metabolism, 50, 113-116.
https://doi.org/10.1210/jcem-50-1-113
|
[4]
|
Chang, R.J., Nakamura, R.M., Judd, H.L., et al. (1983) Insulin Resistance in Nonobese Patients with Polycystic Ovarian Disease. The Journal of Clinical Endocrinology & Metabolism, 57, 356-359.
https://doi.org/10.1210/jcem-57-2-356
|
[5]
|
Dunaif, A., Segal, K.R., Shelley, D.R., et al. (1992) Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome. Diabetes, 41, 1257-1266. https://doi.org/10.2337/diab.41.10.1257
|
[6]
|
Ehrmann, D.A., Sturis, J., Byrne, M.M., et al. (1995) Insulin Secretory Defects in Polycystic Ovary Syndrome. Relationship to Insulin Sensitivity and Family History of Non-Insulin-Dependent Diabetes Mellitus. The Journal of Clinical Investigation, 96, 520-527. https://doi.org/10.1172/JCI118064
|
[7]
|
Nestler, J.E. (1997) Insulin Regulation of Human Ovarian Androgens. Human Reproduction, 12, 53-62.
https://doi.org/10.1093/humrep/12.suppl_1.53
|
[8]
|
Anderson, A.D., Solorzano, C.M.B. and McCartney, C.R. (2014) Childhood Obesity and Its Impact on the Development of Adolescent PCOS. Seminars in Reproductive Medicine, 32, 202-213. https://doi.org/10.1055/s-0034-1371092
|
[9]
|
McCartney, C.R., Blank, S.K., Prendergast, K.A., et al. (2006) Obesity and Sex Steroid Changes across Puberty: Evidence for Marked Hyperandrogenemia in Pre- and Early Pubertal Obese Girls. The Journal of Clinical Endocrinology & Metabolism, 92, 430-436. https://doi.org/10.1210/jc.2006-2002
|
[10]
|
McCartney, C.R., Prendergast, K.A., Chhabra, S., et al. (2006) The Association of Obesity and Hyperandrogenemia during the Pubertal Transition in Girls: Obesity as a Potential Factor in the Genesis of Postpubertal Hyperandrogenism. The Journal of Clinical Endocrinology & Metabolism, 91, 1714-1722. https://doi.org/10.1210/jc.2005-1852
|
[11]
|
Reinehr, T., de Sousa, G., Roth, C.L., et al. (2005) Androgens before and after Weight Loss in Obese Children. The Journal of Clinical Endocrinology & Metabolism, 90, 5588-5595. https://doi.org/10.1210/jc.2005-0438
|
[12]
|
Rojas, J., Chávez, M., Olivar, L., et al. (2014) Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. International Journal of Reproductive Medicine, 2014, Article ID: 719050.
https://doi.org/10.1155/2014/719050
|
[13]
|
Wilroy, R.S., Givens, J.R., Wiser, W.L., et al. (1975) Hyperthecosis, an Inheritance Form of Polycystic Ovary. I. Clinical and Histologic Features. The Journal of Clinical Endocrinology & Metabolism, 22, 326-328.
|
[14]
|
Zhao, H., Lv, Y., Li, L., et al. (2016) Genetic Studies on Polycystic Ovary Syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology, 37, 56-65. https://doi.org/10.1016/j.bpobgyn.2016.04.002
|
[15]
|
Azziz, R., Carmina, E., Chen, Z., et al. (2016) Polycystic Ovary Syndrome. Nature Reviews Disease Primers, 2, 16057.
https://doi.org/10.1038/nrdp.2016.58
|
[16]
|
Rutkowska, A.Z. and Diamanti-Kandarakis, E. (2016) Polycystic Ovary Syndrome and Environmental Toxins. Fertility and Sterility, 106, 948-958. https://doi.org/10.1016/j.fertnstert.2016.08.031
|
[17]
|
Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., et al. (2009) Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. Endocrine Reviews, 30, 293-342. https://doi.org/10.1210/er.2009-0002
|
[18]
|
Bolognesi, C., Castle, L., Cravedi, J.P., et al. (2015) Scientific Opinion on the Risks to Public Health Related to the Presence of Bisphenol A (BPA) in Foodstuffs: Executive Summary. EFSA Journal, 13, 3978.
|
[19]
|
Testai, E. (2016) The Safety of Medical Devices Containing DEHP Plasticized PVC or Other Plasticizers on Neonates and Other Groups Possibly at Risk (2015 Update). Regulatory Toxicology and Pharmacology: RTP, 76, 209.
https://doi.org/10.1016/j.yrtph.2016.01.013
|
[20]
|
Takeuchi, T., Tsutsumi, O., Ikezuki, Y., et al. (2004) Positive Relationship between Androgen and the Endocrine Disruptor, Bisphenol A, in Normal Women and Women with Ovarian Dysfunction. Endocrine Journal, 51, 165-169.
https://doi.org/10.1507/endocrj.51.165
|
[21]
|
Diamanti-Kandarakis, E., Katsikis, I., Piperi, C., et al. (2008) Increased Serum Advanced Glycation End-Products Is a Distinct Finding in Lean Women with Polycystic Ovary Syndrome (PCOS). Clinical Endocrinology, 69, 634-641.
https://doi.org/10.1111/j.1365-2265.2008.03247.x
|
[22]
|
Nelson, V.L., Legro, R.S., Strauss III, J.F., et al. (1999) Augmented Androgen Production Is a Stable Steroidogenic Phenotype of Propagated Theca Cells from Polycystic Ovaries. Molecular Endocrinology, 13, 946-957.
https://doi.org/10.1210/mend.13.6.0311
|
[23]
|
de Faria, F.R., Gusmão, L.S., de Faria, E.R., et al. (2013) Polycystic Ovary Syndrome and Intervening Factors in Adolescents from 15 to 18 Years Old. Revista da Associação Médica Brasileira (English Edition), 59, 341-346.
https://doi.org/10.1016/S2255-4823(13)70485-5
|
[24]
|
Stracquadanio, M. and Ciotta, L. (2017) Low Birth-Weight Is a PCOS Risk Factor for Southern-Italian Women. Gynecological Endocrinology, 33, 373-377. https://doi.org/10.1080/09513590.2017.1283487
|
[25]
|
Pandolfi, C., Zugaro, A., Lattanzio, F., et al. (2008) Low Birth Weight and Later Development of Insulin Resistance and Biochemical/Clinical Features of Polycystic Ovary Syndrome. Metabolism, 57, 999-1004.
https://doi.org/10.1016/j.metabol.2008.02.018
|
[26]
|
Domecq, J.P., Prutsky, G., Mullan, R.J., et al. (2013) Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 98, 4655-4663.
https://doi.org/10.1210/jc.2013-2385
|
[27]
|
Cattrall, F.R. and Healy, D.L. (2004) Long-Term Metabolic, Cardiovascular and Neoplastic Risks with Polycystic Ovary Syndrome. Best Practice & Research Clinical Obstetrics & Gynaecology, 18, 803-812.
https://doi.org/10.1016/j.bpobgyn.2004.05.005
|
[28]
|
Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. (2013) Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 98, 4565-4592.
https://doi.org/10.1210/jc.2013-2350
|
[29]
|
Orio, F., Muscogiuri, G., Giallauria, F., et al. (2016) Oral Contraceptives versus Physical Exercise on Cardiovascular and Metabolic Risk Factors in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Clinical Endocrinology, 85, 764-771. https://doi.org/10.1111/cen.13112
|
[30]
|
Hoeger, K., Davidson, K., Kochman, L., et al. (2008) The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials. The Journal of Clinical Endocrinology & Metabolism, 93, 4299-4306.
https://doi.org/10.1210/jc.2008-0461
|
[31]
|
Lass, N., Kleber, M., Winkel, K., et al. (2011) Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls. The Journal of Clinical Endocrinology & Metabolism, 96, 3533-3540. https://doi.org/10.1210/jc.2011-1609
|
[32]
|
Powers, B.J., Brown, G., Williams, R.W., et al. (2015) Medical Eligibility Criteria for Contraceptive Use. World Health Organization, 87, 276.
|
[33]
|
Cassidenti, D.L., Paulson, R.J., Serafini, P., et al. (1991) Effects of Sex Steroids on Skin 5 Alpha-Reductase Activity in Vitro. Obstetrics and Gynecology, 78, 103-107.
|
[34]
|
Gerlinger, C. and Heithecker, R. (2002) The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea. Cutis, 69, 2-15.
|
[35]
|
中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国治疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6.
|
[36]
|
Natali, A. and Ferrannini, E. (2006) Effects of Metformin and Thiazolidinediones on Suppression of Hepatic Glucose Production and Stimulation of Glucose Uptake in Type 2 Diabetes: A Systematic Review. Diabetologia, 49, 434-441.
https://doi.org/10.1007/s00125-006-0141-7
|
[37]
|
Foretz, M., Guigas, B., Bertrand, L., et al. (2014) Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 20, 953-966. https://doi.org/10.1016/j.cmet.2014.09.018
|
[38]
|
Gooding, H.C., Milliren, C., Paul, M.S., et al. (2014) Diagnosing Dysglycemia in Adolescents with Polycystic Ovary Syndrome. Journal of Adolescent Health, 55, 79-84. https://doi.org/10.1016/j.jadohealth.2013.12.020
|
[39]
|
Speroff, L. and Fritz, M.A. (2005) Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins, Philadelphia.
|
[40]
|
Mazza, A., Fruci, B., Guzzi, P., et al. (2014) In PCOS Patients the Addition of Low-Dose Spironolactone Induces a More Marked Reduction of Clinical and Biochemical Hyperandrogenism than Metformin Alone. Nutrition, Metabolism and Cardiovascular Diseases, 24, 132-139. https://doi.org/10.1016/j.numecd.2013.04.016
|
[41]
|
杨雪萍. 多囊卵巢综合征与肝肾相关说[J]. 河南中医, 2012, 32(2): 144-145.
|
[42]
|
张宁, 刘家义. 痰湿型多囊卵巢综合征临床及内分泌特征分析[J]. 辽宁中医药大学学报, 2010, 12(7): 27-29.
|
[43]
|
李国珍, 阿依努尔. 补肾活血化痰法治疗多囊卵巢综合征56例[J]. 新疆中医药, 2014, 32(2): 16-18.
|
[44]
|
褚娟红, 吴桂珠. 补肾化痰活血法治疗多囊卵巢综合症30例疗效观察[J]. 现代实用医学, 2014, 26(5): 619-620.
|
[45]
|
甘瑾. 补肾祛瘀化痰方联合达英——35治疗多囊卵巢综合征的疗效研究[J]. 中医药学报, 2017, 45(5): 85-87.
|
[46]
|
刘欢妹, 刘宇萌, 魏丹, 孟化. 代谢手术治疗肥胖型多囊卵巢综合征的meta分析[J]. 内蒙古医科大学学报, 2019, 41(2): 139-143.
|
[47]
|
Fitzgerald, D.A. and Baur, L. (2014) Bariatric Surgery for Severely Obese Adolescents. Paediatric Respiratory Reviews, 15, 227-230. https://doi.org/10.1016/j.prrv.2014.06.001
|